| Recent advances in prostate cancer treatment and drug discovery E Nevedomskaya, SJ Baumgart, B Haendler International journal of molecular sciences 19 (5), 1359, 2018 | 262 | 2018 |
| The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage–inducing or repair–compromising therapies in preclinical cancer models AM Wengner, G Siemeister, U Lücking, J Lefranc, L Wortmann, P Lienau, ... Molecular cancer therapeutics 19 (1), 26-38, 2020 | 155 | 2020 |
| Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness V Kari, WY Mansour, SK Raul, SJ Baumgart, A Mund, M Grade, H Sirma, ... EMBO reports 17 (11), 1609-1623, 2016 | 110 | 2016 |
| BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire Z Najafova, R Tirado-Magallanes, M Subramaniam, T Hossan, G Schmidt, ... Nucleic acids research 45 (1), 127-141, 2017 | 107 | 2017 |
| Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models T Sugawara, SJ Baumgart, E Nevedomskaya, K Reichert, H Steuber, ... International Journal of Cancer 145 (5), 1382-1394, 2019 | 65 | 2019 |
| Krüppel-like transcription factor KLF10 suppresses TGFβ-induced epithelial-to-mesenchymal transition via a negative feedback mechanism VK Mishra, M Subramaniam, V Kari, KS Pitel, SJ Baumgart, RM Naylor, ... Cancer research 77 (9), 2387-2400, 2017 | 57 | 2017 |
| RNF40 regulates gene expression in an epigenetic context-dependent manner W Xie, S Nagarajan, SJ Baumgart, RL Kosinsky, Z Najafova, V Kari, ... Genome biology 18, 1-22, 2017 | 46 | 2017 |
| Exploiting epigenetic alterations in prostate cancer SJ Baumgart, B Haendler International journal of molecular sciences 18 (5), 1017, 2017 | 44 | 2017 |
| Histone chaperone SSRP1 is essential for Wnt signaling pathway activity during osteoblast differentiation T Hossan, S Nagarajan, SJ Baumgart, W Xie, RT Magallanes, ... Stem Cells 34 (5), 1369-1376, 2016 | 37 | 2016 |
| Darolutamide antagonizes androgen signaling by blocking enhancer and super‐enhancer activation SJ Baumgart, E Nevedomskaya, R Lesche, R Newman, D Mumberg, ... Molecular oncology 14 (9), 2022-2039, 2020 | 33 | 2020 |
| CHD1 regulates cell fate determination by activation of differentiation-induced genes SJ Baumgart, Z Najafova, T Hossan, W Xie, S Nagarajan, V Kari, N Ditzel, ... Nucleic acids research 45 (13), 7722-7735, 2017 | 30 | 2017 |
| Dysregulated transcriptional control in prostate cancer SJ Baumgart, E Nevedomskaya, B Haendler International Journal of Molecular Sciences 20 (12), 2883, 2019 | 25 | 2019 |
| The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models C Lemos, VK Schulze, SJ Baumgart, E Nevedomskaya, T Heinrich, ... Cellular Oncology 44, 581-594, 2021 | 17 | 2021 |
| MACA: marker-based automatic cell-type annotation for single-cell expression data Y Xu, SJ Baumgart, CM Stegmann, S Hayat Bioinformatics 38 (6), 1756-1760, 2022 | 14 | 2022 |
| Darolutamide potentiates the antitumor efficacy of a PSMA-targeted thorium-227 conjugate by a dual mode of action in prostate cancer models S Hammer, A Schlicker, S Zitzmann-Kolbe, S Baumgart, UB Hagemann, ... Clinical Cancer Research 27 (15), 4367-4378, 2021 | 14 | 2021 |
| Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness V Kari, WY Mansour, SK Raul, SJ Baumgart, A Mund, M Grade, H Sirma, ... EMBO reports 19 (10), e46783, 2018 | 13 | 2018 |
| Single-nucleus RNA sequencing in ischemic cardiomyopathy reveals common transcriptional profile underlying end-stage heart failure B Simonson, M Chaffin, MC Hill, O Atwa, Y Guedira, H Bhasin, AW Hall, ... Cell reports 42 (2), 2023 | 11 | 2023 |
| Fibrotic signaling in cardiac fibroblasts and vascular smooth muscle cells: the dual roles of fibrosis in HFpEF and CAD JC Bachmann, SJ Baumgart, AK Uryga, MH Bosteen, G Borghetti, ... Cells 11 (10), 1657, 2022 | 9 | 2022 |
| CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo SJ Oh-Hohenhorst, D Tilki, AK Ahlers, A Suling, O Hahn, P Tennstedt, ... Cancer Gene Therapy 29 (1), 49-61, 2022 | 7 | 2022 |
| Comparative proteomic and transcriptomic analysis of the impact of androgen stimulation and darolutamide inhibition E Nevedomskaya, T Sugawara, SJ Baumgart, R Lesche, H Hahne, ... Cancers 15 (1), 2, 2022 | 2 | 2022 |
